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INTRODUCTION 
 
Myotonic dystrophy is the most common type of 
muscular dystrophy in adults and is inherited in an 
autosomal dominant manner [1]. There are two 
clinically similar but genetically distinct types: DM 
type 1 (DM1, also known as Steinert’s disease; MIM 
#160900), caused by an unstable expansion of a CTG 
trinucleotide repeat in the noncoding region of the  
 
dystrophia myotonic-protein kinase gene (DMPK) [2], 
and DM type 2 (DM2; MIM #602668), caused by a 
tetra-nucleotide repeat CCTG expansion in the zinc 
finger 9 (ZNF9) gene [3]. CTG and CCTG expansions 
lead to formation of transcript aggregates in the 
nucleus, which interfere with proteins that play an 
important role in RNA metabolism, including 
members of the muscleblind (MBNL) and CUGBP 
RNA-Binding Protein Elav-Like Family Member 1 
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ABSTRACT 
 
Myotonic dystrophy type 1 (DM1; MIM #160900) is an autosomal dominant disorder, clinically characterized by 
progressive muscular weakness and multisystem degeneration. The broad phenotypes observed in patients 
with DM1 resemble the appearance of a multisystem accelerated aging process. However, the molecular 
mechanisms underlying these phenotypes remain largely unknown. In this study, we characterized the impact 
of metabolism and mitochondria on fibroblasts and peripheral blood mononuclear cells (PBMCs) derived from 
patients with DM1 and healthy individuals. Our results revealed a decrease in oxidative phosphorylation 
system (OXPHOS) activity, oxygen consumption rate (OCR), ATP production, energy metabolism, and 
mitochondrial dynamics in DM1 fibroblasts, as well as increased accumulation of reactive oxygen species (ROS). 
PBMCs of DM1 patients also displayed reduced mitochondrial dynamics and energy metabolism. Moreover, 
treatment with metformin reversed the metabolic and mitochondrial defects as well as additional accelerated 
aging phenotypes, such as impaired proliferation, in DM1-derived fibroblasts. Our results identify impaired cell 
metabolism and mitochondrial dysfunction as important drivers of DM1 pathophysiology and, therefore, reveal 
the efficacy of metformin treatment in a pre-clinical setting. 
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(CELF1) families of RNA-binding proteins [4]. Both 
diseases are characterized by missplicing of several 
downstream effector genes with negative effects on 
multiple tissues, thus contributing to the multisystem 
pathogenesis of DM [5]. DM1 is more common than 
DM2 and represents a more severe phenotype. In 
DM1, unaffected individuals carry less than 50 triplet 
repeats, whereas expansions ranging between 50 and 
4000 CTG repeats have been found in affected 
individuals [6].  
 
Patients with DM1 present a multisystem degenerative 
process that includes progressive muscular weakness 
and atrophy, myotonia, cardiomyopathy, insulin-
resistance, cataracts, increased cancer incidence, 
neurodegeneration, metabolic syndrome, or premature 
death. This multisystem degenerative process strongly 
resembles an accelerated aging process [7, 8]. From a 
cellular point of view, different pathogenic mechanisms, 
such as alteration of autophagy, increased senescence, 
telomere shortening, or genomic instability, all of them 
hallmarks of aging [9], have been proposed to explain 
how the expansion in the CTG repeat of affected 
patients leads to the DM multisystem phenotypes [7]. 
However, detailed experimental validation of these 
mechanisms remains incomplete and has not yet been 
clarified. 
 
It is well known the existence of several metabolic 
alterations, which accumulate over time, that affect 
longevity, aging and neurodegeneration [10, 11]. As a 
consequence, deregulated nutrient sensing and 
mitochondrial dysfunction have been proposed as 
hallmarks of aging [9] and metabolism is a pillar of 
aging [12]. In DM1, patients present several metabolic 
defects such as hyperinsulinemia, glucose resistance, 
and, in some cases, diabetes mellitus [7]. Moreover, 
muscle samples in vitro and blood samples in vivo 
show reduced Coenzyme Q10 (CoQ10) levels, a 
component of the electron transport chain that 
participates in aerobic cellular respiration [13, 14], 
which is indicative of mitochondrial dysfunction. 
However, the role of metabolism and mitochondria in 
the pathogenesis of DM1 has not been addressed in 
detail. In this work, we studied their contribution using 
human primary fibroblasts and peripheral blood 
mononuclear cells (PBMCs) derived from healthy 
donors and patients with DM1 as models. Our results 
indicated that DM1 fibroblasts showed impaired 
metabolism and mitochondrial dysfunction resulting in 
lower levels of ATP production and increased reactive 
oxygen species (ROS) production. PBMCs from DM1 
patients also showed impaired mitochondrial dynamics 
and energy homeostasis. Interestingly, treatment with 
metformin resulted in the restoration of these 
phenotypes. 
RESULTS 
 
DM1-derived fibroblasts present impaired 
metabolism 
 
To investigate the role of cellular metabolism in the 
pathogenesis of DM1, we first measured the oxygen 
consumption rate (OCR) in the fibroblasts of patients 
with DM1 and healthy donors. DM1 fibroblasts showed 
a 40% and 50% reduction in basal respiration and 
maximal respiration, respectively, compared to controls, 
which leads to a 50% reduction in ATP production  
via the Mitochondrial Oxidative Phosphorylation 
System (OXPHOS) activity (Figure 1A, 1B). Next, we 
hypothesized that the reduction in OXPHOS activity 
could be responsible for a reduction in the glycolysis 
pathway. To examine this hypothesis, we measured 
extracellular acidification (ECAR) as a measure of 
glycolysis [15]. We did not find any alteration in the 
glycolysis pathway (Supplementary Figure 1A, 1B), 
suggesting that all glucose taken by DM1 fibroblasts 
was coupled to pyruvate production. 
 
The addition of carbonyl cyanide-4 (trifluoromethoxy) 
phenylhydrazone (FCCP) simulates an exacerbated 
physiological energy demand by stimulating the 
respiratory chain to operate at maximum capacity. DM1 
cells were not able to respond to this stress as efficiently 
as controls, farther indicating impaired maximal 
respiration (Figure 1A, 1B). However, we did not find 
any difference in the proton-leak nor the coupling 
efficiency (Figure 1A–1C). Therefore, it seems that all 
the protons generated are coupled to ATP production. 
Moreover, DM1 fibroblasts have a more quiescent 
metabolism compared to healthy controls. In addition, 
after simulating a stress, DM1 fibroblasts could not 
switch to a more energetic metabolism (Figure 1D, 1E), 
resulting in a lower metabolic potential. Consistent with 
these results, DM1 fibroblasts presented lower AKT 
activation (measured as phosphorylated AKT) (Figure 
1F), which is the central mediator of the PI3K pathway 
that serves a key role in multiple cellular processes, 
including glucose metabolism [16]. In summary, DM1-
derived fibroblasts present decreased cellular 
metabolism. 
 
Correlation between impaired metabolism and 
markers of disease pathophysiology 
 
Next, we attempted to associate the impaired 
metabolism of DM1-derived fibroblasts with several 
pathophysiological characteristics of the disease. First, 
we found that the decrease in AKT phosphorylation in 
DM1-derived fibroblasts correlated with lower 
expression of DMPK and MBNL1, both at protein 
(Figure 2A) and mRNA (Figure 2B) levels. Moreover, 
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we examined whether there was a correlation between 
the severity of the metabolic alterations and both the 
number of CTG expansions and the Muscular 
Impairment Rating Scale (MIRS) score. We did not 
detect significant differences in basal and maximal 
respiration or in ATP production when fibroblasts were 
divided into those with less or more than 500 CTG 
repeats and 3 MIRS score (Figure 2C, 2D, 
Supplementary Figure 2). Moreover, there were no 
marked differences between cells obtained from DM1 
patients of different ages, although the cells from a 71 
year-old patient showed slightly higher impairment than 
others (Table 1, Supplementary Figure 3). Overall, 
metabolic dysfunction in fibroblasts derived from 
patients with DM1 seems not to be significantly altered 
by the repeat expansion of these patients. 
DM1-derived fibroblasts display mitochondrial 
dysfunction but no changes in mitochondrial 
biogenesis 
 
The results presented above indicate that the 
mitochondria of patients with DM1 could function 
normally, but with a reduced OXPHOS activity. We 
further investigated this by examining the biogenesis of 
mitochondria [17]. First, we evaluated the levels of two 
markers of mitochondrial content and biogenesis such 
as TOMM20 and PGC1-α. Immunofluorescence 
showed that expression of these two markers was not 
markedly altered in cells from DM1 compared to 
healthy controls (Figure 3A, 3B). In addition, flow 
cytometry was used to analyze another marker of 
mitochondrial content, MitoTracker, obtaining similar 
 
 
 
Figure 1. DM1-derived fibroblasts present impaired metabolism. (A) Kinetic normalized OCR response in DM1 and control fibroblasts 
in basal conditions and after consecutive addition of Oligomycin 1.5 µM, FCCP 1.5 μM and Antimycin-A/Rotenone 1.5 μM. A representative 
experiment out of 3 is shown with 3 independent control cultures and 2 DM1. (B, C) Quantification of mitochondrial respiratory functions and 
coupling efficiency in DM1 (n=7) and control fibroblasts (n=3). (D) Representative energy map and (E) Quantification of metabolic potential of 
DM1 and control fibroblasts. Stressed indicates the values of OCR and ECAR after the injection of oligomycin and FCCP simultaneously. 
Results are obtained from controls (n=3) and DM1 (n=5) cultures. (F) Representative immunoblots of phospho-AKT, AKT, DMPK and MBNL1 in 
DM1-derived fibroblasts and healthy controls (n=3). 
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results. Indeed, no differences were detected in the 
mitochondrial content in DM1 and control cells (Figure 
3C). Moreover, the mitochondrial membrane potential 
remained elevated in DM1 cells (Figure 3D). However, 
the expression of the mitochondrial transcription factor 
A (TFAM) gene that participates in the regulation of the 
mitochondrial genome [18], was reduced by 50% in 
DM1 fibroblasts (Figure 3E). These results suggest that 
the impaired cellular bioenergetics were not related to 
substantial alterations in mitochondrial biogenesis and 
content. 
 
Mitochondria are organelles with high dynamic 
plasticity to rapidly adapt in response to stress 
situations. Mitochondrial dynamic is regulated by a 
machinery of pro-fusion and -fission proteins, which 
constitutes an important part of the mitochondria quality 
control as it facilitates the elimination of damaged 
mitochondria by mitochondrial selective autophagy 
(mitophagy) [19]. We studied the expression of OPA1, 
MFN1 and MFN2 fusion related genes, DRP1 fission 
related gene, and PARKIN, which is involved in 
mitophagy [20]. Interestingly, the levels of OPA1, 
MFN2, DRP1, and PARKIN were decreased in DM1-
derived fibroblasts (Figure 3F). Overall, DM1-derived 
fibroblasts show mitochondrial dysfunction. 
 
DM1-derived blood samples show mitochondria 
dysfunction 
 
Next, we investigated whether these results could be 
translated to the clinical setting. Therefore, we 
measured the expression levels of several of the 
aforementioned genes in PBMCs from a cohort of 
patients with DM1 established in Guipuzcoa (Basque 
Country, Spain) [21]. Interestingly, we found lower 
expression levels of SIRT1, a key metabolic sensor that 
modulates a large variety of cellular processes such as 
energy metabolism stress response and aging [22], 
OPA1 and TFAM (Figure 4), further supporting
 
 
 
Figure 2. Correlation between impaired metabolism and markers of disease pathophysiology. (A) Quantification of protein levels 
shown in Figure 1F (n=4). (B) mRNA levels of DMPK in DM1 fibroblasts (n=7) and controls (n=3). (C) Basal respiration levels in controls (n=3) 
and DM1 fibroblasts stratified by CTG expansion in <500 (n=4) and >500 (n=3) (left) and MIRS scale in <3 (n=2) and >3 n=5 (right). (D) ATP 
production levels using the same stratification. 
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Table 1. Characteristics of human primary fibroblasts.  
Fibroblasts  Status Gender 
Age biopsy 
(years) 
MIRS 
CTG (n) in 
blood 
Age diagnosis 
(years) 
C1 Control M 49       
C2 Control F 48       
C3 Control Unknown 53       
DM1-1 DM1 patient M 71 3 167 53 
DM1-2 DM1 patient F 45 2 333 41 
DM1-3 DM1 patient F 59 3 333 26 
DM1-4 DM1 patient F 44 2 833 27 
DM1-5 DM1 patient M 56 3 1333 20 
DM1-6 DM1 patient F 34 4 1650 12 
DM1-7 DM1 patient M 50 5 233 20 
MIRS: Muscle impairment rating scale; M: male; F: female. 
 
the relevance of the results obtained in cell culture and 
highlighting the importance of metabolism and 
mitochondria for the disease. 
 
DM1-derived fibroblasts present accumulation of 
ROS and p38MAPK activation 
 
Production of ROS is enhanced in several pathological 
conditions in which the respiratory chain is impaired 
[23]. Therefore, we measured ROS production and 
found a 50% increase in total ROS in DM1 cells 
compared to controls (Figure 5A). Similar results were 
obtained when specific ROS produced by the 
mitochondria were measured in DM1 fibroblasts and 
compared to controls (Figure 5B). Further, the 
expression of glutathione peroxidase 1 (GPX1) 
antioxidant gene was decreased by 50% in DM1 cells 
(Figure 5C). In agreement with metabolic studies, we 
 
 
 
Figure 3. DM1-derived fibroblasts have no changes in mitochondria biogenesis. (A, B) Representative images of 
immunofluorescence of TOMM20, and PGC1-α in DM1 and control fibroblasts (n=3). (C) Medium fluorescence intensity of MitoTracker Red 
FM in control (n=3) and DM1 cells (n=5) and (D) of Rhodamine 123 in DM1 and control fibroblasts (n=3). (E) mRNA levels of TFAM 
transcription factor (n=3). (F) mRNA levels of OPA1, MFN1, MFN2, DRP1 and PARKIN in DM1 and control fibroblasts (n≥2). 
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did not observe differences in ROS accumulation when 
fibroblasts were divided based on the number of CTG 
repeats and MIRS score (Figure 5D, 5E). 
 
p38MAPK is a stress-activated protein kinase, which 
accumulates with aging and it is activated by the 
presence of ROS [24, 25]. Consequently, we measured 
the total levels of p38MAPK and its phosphorylated 
form (P-p38MAPK) and found an over 2-fold increase 
in the levels of P-p38MAPK in DM1-derived 
fibroblasts compared to control cells (Figure 5F, 5G). In 
summary, DM1 fibroblasts display increased ROS 
production, which is associated with an enhanced 
activation of p38MAPK.  
 
Metformin restores metabolism and mitochondria 
activity  
 
Metformin is a first-line anti-diabetic agent that 
functions mainly through the suppression of glucose 
production and alleviation of insulin resistance and has 
recently been shown to improve mitochondrial 
respiratory activity [26, 27]. We examined whether 
metformin could improve the impaired OXPHOS 
activity in patients with DM1. To test this idea, we 
treated DM1 and control fibroblasts with 1 μM of 
metformin for 72 hours and evaluated cellular 
metabolism and mitochondrial activity. Interestingly, 
metformin improved the basal oxygen consumption  
rate and maximal respiration of DM1 fibroblasts  
by more than twice (Figure 6A–6C), which resulted  
in an increased ATP production via OXPHOS  
(Figure 6A, 6D). Moreover, it increased the levels of 
OPA1, MFN2, DRP1 and TFAM in DM1 cells by at 
least 1.5-fold (Figure 6E).  
 
 
 
Figure 4. DM1-derived blood samples also show 
mitochondria dysfunction. mRNA levels of SIRT1, OPA1 and 
TFAM in PBMCs derived from DM1 (n≥12) and controls (n=4). 
Next, we measured ROS production and found that 
treatment with metformin significantly decreased ROS 
production in control as well as in DM1 fibroblasts  
(Figure 6F). In accordance, the levels of GPX1 and 
PARKIN were elevated in the presence of metformin in 
DM1 cells (Figure 6G). The levels of SIRT1, a critical 
downstream target, were also induced in DM1 cells 
cultured in the presence of metformin validating the 
effect of metformin in metabolic pathways (Figure 6G). 
In summary, metformin restores the impaired 
metabolism and mitochondrial activity in DM1 
fibroblasts. 
 
Metformin restores additional DM1-associated 
phenotypes  
 
Metformin exerts a potent anti-aging activity, in part by 
increasing proliferation and inhibiting senescence  
[28, 29]. It has been previously reported that DM1 
fibroblasts display decreased cell proliferation and 
enhanced senescence accumulation [8, 30]. Next, we 
investigated the impact of metformin in the proliferative 
potential of DM1 fibroblasts. For this, we treated DM1 
and control fibroblasts with 1 and 10 μM of metformin 
and measured cell viability. As expected, DM1 cells had 
lower viability than controls but, importantly, the 
treatment increased significantly the viability of DM1 
fibroblasts, reaching almost the levels of control cells 
(Figure 7A and Supplementary Figure 4). Moreover, we 
measured the number of cells positive for phospho-
Histone H3 (p-H3) and Ki-67, which are well-
established markers of mitosis and cell division, 
respectively, and found reduced numbers in both 
markers in DM1 cells (Figure 7B–7E). Importantly, 
metformin increased the number of p-H3 and Ki-67 
positive cells by almost 3-fold in DM1 cells (Figure 7C, 
7E). These functional results were further validated at 
the molecular level. Metformin modulated the 
expression of critical genes involved in cell 
proliferation and cell cycle activity such as BMI-1, 
p16INK4a and p21CIP. In particular, treatment for 72 h 
increased the levels of BMI-1, and partially decreased 
the levels of p16INK4a and p21CIP cell cycle inhibitors 
(Figure 7F). Finally, we also detected that metformin 
restored by 1.5-fold the levels of DMPK and MBNL1 
(Figure 7G). Thus, metformin rescues multiple 
phenotypes associated to DM1 cells. 
 
DISCUSSION 
 
We established primary cultures of fibroblasts derived 
from patients with DM1 and found that they display 
impaired metabolism and mitochondrial dysfunction. In 
particular, DM1 fibroblasts present lower production of 
ATP by OXPHOS, less efficient mitochondrial electron 
transport chain, impaired mitochondrial dynamics, and 
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higher production of ROS compared with healthy 
control-derived fibroblasts. Interestingly, some of these 
defects, such as energy homeostasis and mitochondrial 
dynamics, were also detected in PBMCs from patients 
with DM1, together revealing the impact of metabolism 
and mitochondrial function on the pathophysiology of 
DM1.  
 
These results show that fibroblasts, which are a well-
established model for cell aging studies in vitro [31], 
might be a good cellular model to characterize the 
pathophysiology of the disease, as they resemble 
multiple molecular and cellular phenotypes of the 
disease. However, we did not detect a correlation 
between the severity of the phenotypes and the number 
of CTG repeats. This result might be potentially biased 
by methodological reasons because CTG expansion was 
measured several years before isolation of skin 
fibroblasts and blood samples. In addition, some 
experiments were performed at early passage. 
 
Our results reveal novel processes involved in the 
pathophysiology of the disease. Indeed, the role of 
mitochondria in DM1 remained practically unknown. A 
previous study observed an inverse correlation between 
the expression of CoQ10, an electron carrier in the 
mitochondrial respiratory chain, and lactate production 
with CTG expansion in PBMC samples [14], whereas 
mitochondrial dysfunction was suggested to occur in 
muscles of patients with DM1 as well [32]. The results 
of these studies are in line with our data and are 
indicative of mitochondrial dysfunction in DM1. The 
lower mitochondrial efficiency detected in our study 
could be due to the conversion of pyruvate, generated 
  
 
 
Figure 5. DM1-derived fibroblasts present accumulation of ROS and p38MAPK activation. (A) Luminescence signal proportional to 
H2O2 production in DM1 (n=4) and control fibroblasts (n=3). (B) Medium fluorescence intensity of MitoSOX+ values normalized to mean 
fluorescence of MitoTracker values in controls (n=3) and DM1 (n=5). (C) GPX1 mRNA levels in DM1 and control fibroblasts (n≥2). (D) 
Luminescence signal proportional to H2O2 production in controls (n=3) and DM1 fibroblasts stratified by CTG expansion in <500 CTG (n=3) and 
>500 CTG (n=1). (E) Medium fluorescence intensity of MitoTracker Red FM in controls (n=3) and DM1 stratified by CTG expansion in <500 
(n=3) and >500 (n=2) (left) and MIRS scale in <3 (n=2) and >3 (n=3) (right). (F, G) Representative immunoblot and quantification of P-
p38MAPK and p38MAPK protein levels in DM1 and control fibroblasts (n=3). 
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during glycolysis, to lactate instead of acetyl CoA, which 
is transported to mitochondria and enters into the Krebs 
cycle. Moreover, our results show that mitochondrial 
biogenesis seems to be normal in DM1 cells, but they are 
not able to maintain the metabolic state as a consequence 
of unbalance remodeling of mitochondrial network 
morphology, which is not correctly controlled by the 
machinery of pro-fusion and fission proteins, and 
impaired elimination through mitophagy.  
 
DM1 patients develop a large variety of symptoms in 
multiple systems that strongly resemble the clinical signs 
of accelerated aging, including some related to 
metabolism and mitochondria dysfunction such as insulin 
resistance, glucose intolerance, hyperinsulinemia, and 
increased risk of type 2 diabetes [33, 34]. Our results 
shed light in the underlying molecular mechanisms of 
these symptoms. Given that mitochondria is the main 
energy hub of the cell and the main intracellular source of 
ROS, our results might be extended to additional DM1 
symptoms, particularly in the muscle, since a shift in 
energy production anticipates muscle atrophy with aging. 
Finally, our results further support the link between DM1 
and accelerated aging [8], since cellular metabolism and 
mitochondrial dysfunction are critical mechanisms in 
aging. 
 
 
 
Figure 6. Metformin restores OXPHOS activity and ROS production in DM1 fibroblasts. (A) Representative kinetic normalized OCR 
response in DM1 (n=6) and control fibroblasts (n=3) after treatment with 1 μM of metformin for 72 h. DM1 and control fibroblasts were 
plated at 5.000 cells/well 24 hours prior to the assay. A representative experiment out of 3 is shown. (B–D) Quantification of mitochondrial 
basal respiration, maximal respiration, and ATP production respectively after treatment with 1 μM of metformin for 72 h of controls (n=3) 
and DM1 fibroblasts (n=6). (E) mRNA levels of OPA1, MFN1, MFN2, DRP1 and TFAM after treatment with 1 μM of metformin for 72 h (n≥2). 
(F) H2O2 production after treatment with 1 μM of metformin for 72 h (n=3). (G) mRNA levels of SIRT1, GPX1 and PARKIN in DM1 and control 
fibroblasts after treatment with 1 μM of metformin 72 h (n≥2). 
 
 www.aging-us.com  6268 AGING 
DM1 is a rare, clinically variable disease with no 
currently available treatment to slow or stop disease 
progression. Supportive treatments, preventive 
measures and clinical surveillance are the only 
options available for patients with DM1 [35]. 
Metformin is a synthetic biguanide that is currently 
one of the most recommended medications for type 2 
diabetes treatment around the world. Interestingly, 
studies in both vertebrates and invertebrates have 
shown that metformin delays aging and increases 
longevity [29]. Moreover, a meta-analysis has 
suggested that metformin reduces all-cause mortality 
and aging-related diseases in humans independent of 
its effect on diabetes [36]. We show here that 
metformin improves ATP production by OXPHOS 
and decreases the production of ROS in DM1 cells 
even at a much lower concentration compared to its 
current therapeutic dose (1 μM vs 75 μM). In line with 
our results, it has been recently shown that 
mitochondria might be a target of metformin [27]. We 
also found that metformin treatment reverses 
additional DM1-related phenotypes such as impaired 
proliferation, suggesting that its mechanism of action 
in DM1 is wider. In support, low doses of metformin 
may also correct several alternative splicing defects in 
DM1 myoblasts in vitro [37], the use of metformin 
reduced the risk of cancer in patients with DM1 
having diabetes [38], and also improved mobility of 
DM1 patients in a small randomized clinical trial [39]. 
If the hypothesis of an accelerated aging in patients 
with DM1 is validated, our results could be added to 
the potential benefits of expanding metformin use in 
DM1, outside of the management of T2D, to include 
cancer prevention [38] and also phenotypes associated 
with aging. In summary, our results showed the 
efficacy of metformin in a pre-clinical setting and 
suggest that it warrants further assessment as a 
candidate drug for DM1 treatment.  
 
 
 
Figure 7. Metformin restores cell viability and proliferation in DM1 fibroblasts. (A) Cell viability of DM1 (n=5) and control (n=3) 
fibroblasts measured in MTT studies after treatment with 1 μM of metformin for 72 h. (B, C) Representative image and quantification of p-H3 
(Ser10) staining in the same conditions in controls (n=3) and DM1 (n=7). (D, E) Representative image of Ki-67 staining and quantification in 
controls (n=2) and DM1 cells (n=3). (F) mRNA levels of BMI-1, p16INK4a and p21CIP in cells treated or not with 1 μM of metformin for 72 h (n≥2). 
(G) mRNA levels of DMPK and MBNL1 in the same conditions (n=3). 
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MATERIALS AND METHODS 
 
Study approval 
 
This study was approved by the Donostia University 
Hospital Ethical Board (approval number 15-57) and 
was conducted in accordance with the Declaration of 
Helsinki’s ethical standards. All subjects gave written 
informed consent before sample donation.  
 
Reagents and cell culture 
 
For the isolation of primary fibroblasts, punch skin 
biopsies were chopped into 2–3 mm3 fragments and 
placed on a surface moistened with modified Eagle’s 
medium containing 13% newborn calf serum, 0.4% 
penicillin/streptomycin (Gibco, Waltham, MA, USA) 
and 2 mM L-glutamine (Gibco). Flasks were incubated 
vertically for 3–6 hours at 37 °C in a 5% CO2 
atmosphere and then returned to the horizontal 
position. Human fibroblasts were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM, Gibco) 
containing 10% fetal bovine serum (FBS) (Sigma-
Aldrich, St Louis, MO, USA), 1% L-glutamine (Gibco) 
and 1% penicillin/streptomycin (Gibco). 7 independent 
cultures from different patients with DM1 and 3 from 
healthy controls were established (see Table 1 for 
patient characteristics). When indicated, fibroblasts 
were treated with metformin (Sigma-Aldrich) for 72 
hours. Experiments were performed in early passage 
cultures (range of 5 to 10 passages).  
 
Metabolic measurements 
 
Measurement of OCR and ECAR were performed in 
XF96 plates with XF Extracellular Flux Analyzer 
(Seahorse Bioscience). Fibroblasts were seeded in 
collagen (BD Biosciences) coated XF 96-well plates 
(Seahorse/Agilent) in octuplicates at 1.2x104 cells/well 
in 100 μl of growth medium. Mitochondrial activity 
was evaluated using the Seahorse XF Cell Mito stress 
Test Kit, according to manufacturer’s instructions 
(Agilent). In the metformin treatment experiments, 
cells were plated at 5x103 cells/well 24–28 hours prior 
to the assay. Oligomycin (75351, Sigma-Aldrich), 
FCCP (C2920, Sigma-Aldrich), and 
Rotenone/Antimycin A (R8875 and A8674, Sigma-
Aldrich) were used at 1.5 μM concentration, after a 
titration experiment. Glycolytic activity was evaluated 
using the XF Glycolysis Stress Test according to 
manufacturer’s instructions (Agilent). Glucose (G8769, 
Sigma-Aldrich) was used at 10 mM, oligomycin at 1 
μM and 2-D-Deoxy-Glucose at 50 mM (D6134, Sigma-
Aldrich). Cell content was normalized using crystal 
violet. The post-normalization values of OCR and 
ECAR reflect both the metabolic activities of the cells 
and the number of cells being measured. Data were 
further processed according to manufacturer’s 
instructions.  
 
Total ROS measurement 
 
A total of 1x103 fibroblasts were plated in 96-well 
plates and grown for 3 days. Afterwards, ROS-Glo 
H2O2 Assay (G8820, Promega) was performed 
according to the manufacturer’s instructions. Briefly, a 
H2O2 substrate reacts directly with H2O2 to generate a 
luciferin precursor and, upon addition of a detection 
reagent, this precursor is converted to luciferin, which 
generates a luminescent signal that is proportional to 
the H2O2 concentration. White flat bottom plates 
(Corning) were used for final readout in a PHERAstar 
(BMG Labtech) luminometer plate reader. 
 
Mitochondrial ROS production and mitochondrial 
content measurement 
 
Mitochondrial ROS analysis was performed using the 
dye MitoSOX (M36008, Invitrogen). Mitochondrial 
content was assayed using the dye MitoTracker FM 
(M22425, Invitrogen), which passively diffuses across 
the plasma membrane and accumulates in active 
mitochondria. 
 
20x104 fibroblasts per condition were grown for two 
days, reaching 70% confluence in p100 plates. Cells 
were detached using trypsin for 5 min at 37 °C. For 
MitoSOX staining, cells were washed once using warm 
HBSS, incubated with 5 μM of MitoSOX in HBSS for 
30 min at 37 °C, washed 3x using warm HBSS and 
suspended in HBSS. For MitoTracker staining, cells 
were washed with PBS, incubated with 0.2 μM 
MitoTracker for 30 min at 37 °C, washed 3x using 
warm PBS and suspended in PBS. Cells were directly 
analyzed via flow cytometry. In FSC and SSC, we first 
gated the population; next, two gates were set on SSC-
A vs. SSC-H and SSC-A vs. SSC-W to exclude 
doublets. Based on an unstained control, MitoSOX+ 
and MitoTracker+ gates were set. Mean fluorescence of 
MitoSOX+ was normalized as a mean fluorescence of 
MitoTracker values, which represents ROS production 
per mitochondria. Antimycin was used as a positive 
control and FCCP as a negative control. 
 
Mitochondrial membrane potential measurement 
 
20x104 fibroblasts per condition were grown for 2 days, 
reaching 70% confluence in p100 plates. Cells were 
detached using trypsin for 5 min at 37 °C. We used 1 
μM of Rhodamine 123 (Invitrogen) for 15 min at 37 °C 
to measure the mitochondrial membrane potential. This 
probe is readily sequestered by functioning 
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mitochondria and is easily washed out of cells once the 
mitochondria experience a loss in membrane potential. 
 
Cell viability 
 
Fibroblasts were seeded in 96-well plates followed by 
treatment with metformin for 72 h. Viable cells were 
quantified using the modified 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma-
Aldrich) assay in six replicates per condition. 
 
mRNA expression analysis 
 
Total RNA was extracted using TRIzol (Life 
Technologies). Reverse transcription was performed 
using random priming and the Maxima First Strand 
cDNA Synthesis Kit for RT-qPCR, with dsDNase 
(Thermo Fisher Scientific, Waltham, MA, USA), 
according to the manufacturer’s guidelines. Quantitative 
PCR was performed using Power SYBR Green PCR 
Master Mix (Thermo Fisher Scientific), 10 mM of each 
primer and 20 ng of cDNA, in a CFX384 thermocycler 
(Bio-Rad, Hercules, CA, USA). Primer sequences will 
be given upon request. Variations in RNA input were 
corrected by analyzing the expression of GAPDH as a 
housekeeping gene. The ΔΔCT method was used for 
relative quantification. 
 
Western blot and immunofluorescence analysis 
 
Immunoblot and immunofluorescence assays were 
performed following standard procedures, as 
previously described [40]. Primary antibodies were: 
phospho Histone H3 Ser10 (ab14955, Abcam), 
TOMM20 (11802-1-AP, Proteintech), PGC1-α 
(NBP1-04676, Novus Biologicals), phospho 
p38MAPK Thr180/Tyr182 (9211, Cell Signaling), 
p38MAPK (sc-7972, Santa Cruz Biotechnology) 
AKT1/2/3 (sc-8312, Santa Cruz Biotechnology), 
phospho AKT Ser 473 (9271, Cell Signaling), DMPK 
(sc-134319, Santa Cruz Biotechnology), MBNL1 
(ab45899, Abcam) and β-actin (AC-15, Sigma-
Aldrich). For western blot detection of primary 
antibodies, we used HRP-linked antibodies (Santa 
Cruz Biotechnology) and the detection was performed 
by chemiluminescence using Novex ECL Chemi 
Substrate (Thermo Fisher). For immunofluorescence, 
nuclear DNA was stained with Hoechst (33342, 
Sigma-Aldrich). 
 
Statistics 
 
Data are presented as mean values ± S.E.M., with the 
number of experiments (n) in parentheses. Unless 
otherwise indicated, statistical significance (p-values) 
was calculated using the Student´s t-test. Asterisks (*, 
**, and ***) indicate statistical significance (p < 0.05, p 
< 0.01, and p < 0.001, respectively).  
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SUPPLEMENTARY MATERIAL 
 
Supplementary Figures 
 
 
 
Supplementary Figure 1. DM1-derived fibroblasts have no changes in glycolysis. (A) Kinetic normalized ECAR response in DM1 and 
control fibroblasts obtained in basal conditions and after consecutive addition of Glucose 10 mM, Oligomycin 1 μM and 2-D-Deoxy-Glucose 
50 mM. DM1 and control fibroblasts were plated at 5x103 cells/well, in XF96 cell culture plates, 24–28 h prior to the assays. The assay 
medium was the substrate-free base medium supplemented with 2 mM glutamine. Upon completion of an assay, cells were normalized using 
violet crystal. A representative experiment is shown here (n=3 controls and n=4 DM1 patients). (B) Quantification of glycolytic functions in 
DM1 and control fibroblasts (n=3 controls and n=4 DM1 patients).  
 
 
 
 
 
Supplementary Figure 2. No differences in maximal respiration of DM1 fibroblasts stratified by CTG amplification and MIRS 
scale. (A) Maximal respiration in fibroblasts derived from controls (n=3) and DM1 patients stratified by CTG expansion in <500 CTG (n=4) and 
>500 (n=3). (B) Maximal respiration in fibroblasts derived from controls (n=3) and DM1 patients stratified by MIRS scale in <3 (n=2) and >3 
(n=5). 
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Supplementary Figure 3. Comparison of results in DM1 fibroblasts based on patient age. (A) Analysis of Basal respiration. (B) 
Maximal respiration, (C) ATP production and (D) H2O2 production in control fibroblasts (control; black) (n=3), in DM1-derived fibroblasts 
excluding a 71 years-old case (DM1; blue) (n=6), and cells derived from a 71 years-old patient (DM1; grey). 
 
 
 
 
Supplementary Figure 4. Metformin restores cell viability in DM1-derived fibroblasts. Cell viability after treatment with 1 and 10 
mM of metformin for 72 h. Figure shows results from controls (n=3) and DM1 (n=5) cells.  
